IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
artículos
Título:
Effects of Methotrexateonil-6alphar, VCAM-1 and NF Kappa B Expression in a Rat Model of Metabolic Syndrome
Autor/es:
GARCIA RD; MIATELLO RM; RAMIREZ JM; RENNA NF; DIEZ E
Revista:
journal of hypertension and management
Editorial:
ClinMed International Library
Referencias:
Lugar: New York; Año: 2016 vol. 2 p. 1 - 6
ISSN:
2474-3690
Resumen:
BACKGROUND: In this study, we used methotrexate (Mtx) to examine the role of immunomodulation on the activation of IL-6 and VCAM-1, which could generate a microenvironment that supports cardiovascular remodelling.METHODS: Male WKY and SHR rats were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+Mtx (0,3 mg/kg intraperitoneal one injection per day week for 6 weeks) (n=8 per group). Metabolic variables and systolic blood pressure were measured. Cardiac and vascular remodelling was also evaluated. To assess this, IL-6R and VCAM-1 immunostaining techniques were used.RESULTS: The FFHR experimental model developed metabolic syndrome, vascular and cardiac remodelling, and vascular inflammation because of increased expression of IL-6 and VCAM-1. Chronic treatment with Mtx completely or partiality reversed the variables studied.CONCLUSIONS: The results demonstrated an impact on immunomodulation after mtx treatment, which included a reduction in vascular inflammation and a favourable reduction in metabolic and structural parameters.